Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program

Conclusions These data demonstrate encouraging activity and tolerability of regorafenib in routine clinical practice. The documented adverse events are in line with previous trial data.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research